Tianli International Holdings Limited (01773) executive director Luo Shi increased his holdings by a total of 300,000 shares.
Tianli International Holdings Limited (01773) announced that on January 30, 2026, Mr. Luo (Executive Director, Chairman and Chief Executive Officer of the Company) purchased a total of 300,000 ordinary shares of the Company in open market transactions, representing approximately 0.01% of the total number of issued shares of the Company (i.e. 2.109 billion shares), at an average price of approximately HK$2.79 per share.
TIANLI INT HLDG (01773) announced that on January 30, 2026, Mr. Luo (Executive Director, Chairman and CEO of the Company) purchased a total of 300,000 shares of the company's common stock in the open market, representing approximately 0.01% of the total issued shares of the company (21.09 billion shares) at an average price of approximately HK$2.79 per share. Following the purchase, Mr. Luo directly and indirectly holds a total of 922 million shares of the company, representing approximately 44.09% of the total issued shares of the company as of the date of this announcement (excluding 13.227 million shares repurchased but not yet cancelled as of the date of this announcement and 4.2 million treasury shares held by the company). Mr. Luo has also been granted 30 million share options under the share option scheme, giving him the right to subscribe for 30 million shares, which are currently unexercised.
On January 30, 2026, the company repurchased 200,000 shares of its own stock in the open market, representing approximately 0.0095% of the total issued shares of the company. The repurchased shares will be held by the company as treasury shares.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


